Krembil's annual report features commercialization partnership

The latest issue of The Krembil, the official newsletter of the Krembil Research Institute (formerly the Toronto Western Research Institute) is now available. Research at Krembil is focused on finding innovative treatments and cures for chronic debilitating disorders, including arthritis and diseases of the brain and eyes.

Stories in this month’s issue include the launch of Krembil's latest annual report, titled “Science Powering Discovery”, which can be viewed here(link is external).  The 2021 annual report features our commercialization partnership with Lucid Psycheceuticals - read more on page 22.(link is external)

Other stories featured in this issue of the newsletter include:

● A Historic Gift: UHN celebrates a transformative gift to the Donald K. Johnson Eye Institute.
● Dementia Researcher Joins Krembil: Dr. Martin Ingelsson studies the mechanisms underlying Alzheimer disease and related dementias.

● A Wave of Discovery: Study reveals key determinants of a pattern of brain activity that is important for memory.
● Homing in on a Target: Researchers clarify disease mechanisms and therapeutic targets in axial spondyloarthritis.
● Light at the End of the Tunnel: Cells transplanted into the retina transfer materials to recipient cells through nanotubes.
● A New Model for Osteoarthritis: Researchers devise a fast and robust method to test potential therapies for osteoarthritis.

Read these stories here(link is external). To read previous issues, see the newsletter archive(link is external).

Source: UHN Research News

‍